Protara reports 68% six-month CR rate in TARA-002 trial; triggers warrant exercise period

Protara Therapeutics, Inc.

Six-month complete response (CR) rate of 68.0% in 25 BCG-unresponsive NMIBC patients in Phase 2 ADVANCED-2 trial.
CR rate is consistent with the 68.2% announced on February 24, 2026, and meaningfully above 41.9% threshold.
Condition met for fixing termination date of April 2024 common stock warrants; exercisable at $5.25 through June 29, 2026.
Results from open-label trial; further updates may be required for regulatory discussions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.